NCT00908349已完成3 期
Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 214
- 主要终点
- Percent Change in Seizure Rate
研究概览
简要总结
Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR)
详细描述
NAP
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 66 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Oxcarbazepine XR
Other
Open Label Study
干预措施: Oxcarbazepine XR (Drug)
结局指标
主要结局
Percent Change in Seizure Rate
时间窗: one year
Measured as change from baseline to end of study
次要结局
未报告次要终点
研究者
相似试验
已完成
4 期
Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I DisorderBipolar DisorderNCT00139594Novartis181
终止
3 期
Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic RetinopathyDiabetic RetinopathyNCT00248157Novartis Pharmaceuticals105
终止
3 期
Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic RetinopathyDiabetic RetinopathyNCT00248131Novartis Pharmaceuticals260
终止
3 期
Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor FluctuationsParkinson's DiseaseNCT00505622Eisai Limited328
已完成
1 期
A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on PadsevonilEpilepsyNCT03695094UCB Biopharma S.P.R.L.31